Ashish Kamat is joined by Jens Bedke to discuss BCG treatment and the global shortage in bladder cancer care. Professor Bedke shares insights from a study of 1,900 high-risk non-muscle invasive bladder carcinoma patients, revealing that only two-thirds received the recommended BCG therapy. He discusses significant regional differences in BCG availability, with Germany having better access…Read More
